OPK Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of -12425.36%. OPKO Health, Inc.'s return on equity of -13.5% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 173.72%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than OPKO Health, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than OPKO Health, Inc..

OPKO Health, Inc. has a beta of 1.343, which suggesting that the stock is 34.307% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

OPKO Health, Inc. quarterly revenues are $151.7M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. OPKO Health, Inc.'s net income of $21.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.62x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solventum Corp. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of 60.4%. OPKO Health, Inc.'s return on equity of -13.5% beat Solventum Corp.'s return on equity of 42.2%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 173.72%. On the other hand Solventum Corp. has an analysts' consensus of $85.64 which suggests that it could grow by 6.81%. Given that OPKO Health, Inc. has higher upside potential than Solventum Corp., analysts believe OPKO Health, Inc. is more attractive than Solventum Corp..

OPKO Health, Inc. has a beta of 1.343, which suggesting that the stock is 34.307% more volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.

OPKO Health, Inc. quarterly revenues are $151.7M, which are smaller than Solventum Corp. quarterly revenues of $2.1B. OPKO Health, Inc.'s net income of $21.6M is lower than Solventum Corp.'s net income of $1.3B. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while Solventum Corp.'s PE ratio is 9.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.62x versus 1.67x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of 14.18%. OPKO Health, Inc.'s return on equity of -13.5% beat Stryker Corp.'s return on equity of 14.06%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 173.72%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 20.68%. Given that OPKO Health, Inc. has higher upside potential than Stryker Corp., analysts believe OPKO Health, Inc. is more attractive than Stryker Corp..

OPKO Health, Inc. has a beta of 1.343, which suggesting that the stock is 34.307% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OPKO Health, Inc. quarterly revenues are $151.7M, which are smaller than Stryker Corp. quarterly revenues of $6.1B. OPKO Health, Inc.'s net income of $21.6M is lower than Stryker Corp.'s net income of $859M. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while Stryker Corp.'s PE ratio is 46.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.62x versus 5.62x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of 17.41%. OPKO Health, Inc.'s return on equity of -13.5% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 173.72%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 24.96%. Given that OPKO Health, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe OPKO Health, Inc. is more attractive than West Pharmaceutical Services, Inc..

OPKO Health, Inc. has a beta of 1.343, which suggesting that the stock is 34.307% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OPKO Health, Inc. quarterly revenues are $151.7M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. OPKO Health, Inc.'s net income of $21.6M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 40.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.62x versus 6.68x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.